> *SunPharma* ⛑️ - Revenue guidance for FY26 will be in mid-to-high single digits - The Company will maintain growth trajectory in speciality sales. Adds, they are well positioned to launch Semaglutide in India & EMs. Watch - https://youtu.be/E5DXe17GFiE?si=5paWs8Av6dOK-6kW